Brookline Capital Management Forecasts NTLA FY2030 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Management issued their FY2030 earnings estimates for shares of Intellia Therapeutics in a research note issued to investors on Tuesday, January 27th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $75.05 for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter in the prior year, the business earned ($1.34) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis.

A number of other equities analysts have also weighed in on NTLA. Tudor Pickering set a $14.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a report on Friday, November 7th. William Blair downgraded Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Robert W. Baird set a $7.00 price target on Intellia Therapeutics in a research report on Tuesday. Finally, Truist Financial reissued a “buy” rating and set a $14.00 price objective (down previously from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of “Hold” and an average target price of $17.19.

Intellia Therapeutics Stock Performance

NTLA stock opened at $14.83 on Wednesday. The stock has a fifty day moving average of $10.11 and a 200-day moving average of $12.93. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.47 and a beta of 2.05.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after buying an additional 192,651 shares in the last quarter. Contrarius Group Holdings Ltd raised its stake in shares of Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of Intellia Therapeutics by 2.7% in the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after acquiring an additional 71,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock valued at $24,449,000 after purchasing an additional 126,049 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Intellia Therapeutics by 7.6% during the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after purchasing an additional 173,033 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. The trade was a 3.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 53,051 shares of company stock worth $488,600. 3.10% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.